BTCY vs. LUCD, ICAD, DRIO, TTOO, RVP, MODD, ICCM, AKLI, GBS, and MDAI
Should you be buying Biotricity stock or one of its competitors? The main competitors of Biotricity include Lucid Diagnostics (LUCD), iCAD (ICAD), DarioHealth (DRIO), T2 Biosystems (TTOO), Retractable Technologies (RVP), Modular Medical (MODD), IceCure Medical (ICCM), Akili (AKLI), GBS (GBS), and Spectral AI (MDAI). These companies are all part of the "surgical & medical instruments" industry.
Biotricity (NASDAQ:BTCY) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.
Biotricity has a net margin of -125.43% compared to Lucid Diagnostics' net margin of -1,576.60%. Biotricity's return on equity of 0.00% beat Lucid Diagnostics' return on equity.
Lucid Diagnostics received 28 more outperform votes than Biotricity when rated by MarketBeat users. Likewise, 62.22% of users gave Lucid Diagnostics an outperform vote while only 0.00% of users gave Biotricity an outperform vote.
Lucid Diagnostics has a consensus target price of $4.33, indicating a potential upside of 462.04%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than Biotricity.
3.9% of Biotricity shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 20.5% of Biotricity shares are held by insiders. Comparatively, 4.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Biotricity has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.
Biotricity has higher revenue and earnings than Lucid Diagnostics. Biotricity is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Biotricity and Biotricity both had 2 articles in the media. Biotricity's average media sentiment score of 0.00 beat Lucid Diagnostics' score of -0.67 indicating that Biotricity is being referred to more favorably in the media.
Summary
Lucid Diagnostics beats Biotricity on 11 of the 17 factors compared between the two stocks.
Get Biotricity News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTCY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BTCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biotricity Competitors List
Related Companies and Tools
